# Methods (ARRIVE 2.0 호환 초안)

- 동물 모델: HFD+OVX, HFD+aging
- 처치 군 (4): bimagrumab, tirzepatide, tirzepatide+bimagrumab, vehicle
- 군별 n: bimagrumab=8, tirzepatide=8, tirzepatide+bimagrumab=8, vehicle=8
- Randomization seed: cohort_meta.csv 기록
- Endpoint: BW, EchoMRI/qNMR body composition, grip strength force-meter, treadmill exhaustion, micro-CT muscle CSA, myofiber HCS imaging summary, myokine ELISA(myostatin/activin A/irisin/decorin/BAIBA)
- 분석: baseline lock(W0), per-mouse % change, median±IQR per arm, sarcopenic obesity composite endpoint(BW<-5% AND lean>-3% AND grip/lean>+5%), muscle-sparing decompose(monotherapy slope 기반 expected vs actual), fiber type protection 패턴(IIB>IIX>IIA>I).
- 통계: scipy.stats.linregress, median/IQR; α=0.05 (multiple comparisons는 future scope).
- 디스클레이머: 합성 demo 데이터는 약물 효과 시그널을 단순화한 합성치이며 실제 전임상/임상 반응을 대체하지 않음.